Journal: Journal of Clinical Microbiology
Article Title: Leveraging patient data to detect systematic shifts in daptomycin susceptibility testing associated with reduced prescribing
doi: 10.1128/jcm.01510-25
Figure Lengend Snippet: Daptomycin AST results at BJH and HUP. ( A, D ) The monthly fraction of index clinical isolates (e.g., first per patient encounter) of Enterococcus faecium, Enterococcus faecalis, Staphylococcus aureus, and Staphylococcus epidermidis and testing susceptible (S) or susceptible dose-dependent (SDD). ( B, E ) Daptomycin MIC values for index Enterococcus faecium clinical isolates. ( C, F ) Daptomycin MIC values for the Staphylococcus aureus ATCC 29213 quality control strain. In panel A, the shaded regions indicate the 95% confidence interval. In panels B and C , marker color indicates a result categorized as S or SDD (gray) or not susceptible (red), and lines and shaded regions indicate the monthly median and interquartile range (25th–75th percentile), respectively. In all panels, the vertical dashed lines represent change points determined for the data in the left side of panel A , and the triangle markers denote the timing of institution-specific daptomycin ETEST lot changes. Horizontal lines in C indicate the acceptable CLSI QC range.
Article Snippet: This one doubling dilution shift was mirrored in the QC results at BJH ( ; ) where the median daptomycin MIC for the S. aureus ATCC 29213 QC strain went from 0.5 μg/mL in the baseline epoch to 1.0 ( P < 0.0001) and then back to 0.5 ( P = 0.132) in the affected and recovery epochs, respectively.
Techniques: Control, Marker